Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin–biotin technology: Formulation development and in vitro anticancer activity

Pulkkinen, Mika; Pikkarainen, Jere T.; Wirth, Thomas; Tarvainen, Tanja; Haapa-aho, Vesa; Korhonen, Harri; Seppälä, Jukka; Järvinen, Kristiina

doi:10.1016/j.ejpb.2008.04.018

Cited by 112 publications

(62 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…New formulations that overcome these problems will have clear clinical advantages. In recent years, various groups of researchers have investigated the development of novel formulations for PTX, including liposomes, [10][11][12][13][14][15] emulsions, [16][17][18][19] cyclodextrins, [20][21][22] microspheres, 23,24 nanoparticles, [25][26][27][28][29][30][31] and implants. [32][33][34][35] In addition, injectable thermoreversible hydrogels are also being developed with reasonable success for PTX delivery.…”

Section: Introductionmentioning

confidence: 99%

Thermoreversible Pluronic® F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies

Nie¹,

Hsiao²,

Pan³

et al. 2011

IJN

117

View full text Add to dashboard Cite

Purpose To develop an in situ gel system comprising liposome-containing paclitaxel (PTX) dispersed within the thermoreversible gel (Pluronic ® F127 gel) for controlled release and improved antitumor drug efficiency. Methods The dialysis membrane and membrane-less diffusion method were used to investigate the in vitro drug release behavior. Differential scanning calorimetry (DSC) thermal analysis was used to investigate the “micellization” and “sol/gel transition” process of in situ gel systems. In vitro cytotoxicity and drug uptake in KB cancer cells were determined by MTT, intercellular drug concentration, and fluorescence intensity assay. Results The in vitro release experiment performed with a dialysis membrane model showed that the liposomal gel exhibited the longest drug-release period compared with liposome, general gel, and commercial formulation Taxol ® . This effect is presumably due to the increased viscosity of liposomal gel, which has the effect of creating a drug reservoir. Both drug and gel release from the in situ gel system operated under zero-order kinetics and showed a correlation of release of PTX with gel, indicating a predominating release mechanism of the erosion type. Dispersing liposomes into the gel replaced larger gel itself for achieving the same gel dissolution rate. Both the critical micelle temperature and the sol/gel temperature, detected by DSC thermal analysis, were shifted to lower temperatures by adding liposomes. The extent of the shifts depended on the amount of embedded liposomes. MTT assay and drug uptake studies showed that the treatment with PTX-loaded liposomal 18% Pluronic F127 yielded cytotoxicities, intercellular fluorescence intensity, and drug concentration in KB cells much higher than that of conventional liposome, while blank liposomal 18% Pluronic F127 gel was far less than the Cremophor EL ® vehicle and empty liposomes. Conclusions A thermosensitive hydrogel with embedded liposome is a promising carrier for hydrophobic anticancer agents, to be used in parenteral formulations for treating local cancers.

show abstract

Section: Introductionmentioning

confidence: 99%

Thermoreversible Pluronic® F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies

Nie¹,

Hsiao²,

Pan³

et al. 2011

IJN

117

View full text Add to dashboard Cite

show abstract

“…14,15 The common end-group forms of PEG-PLA derivatives include hydroformylation, propylene acylation, and amination. 16 For example, Salem et al 17 first linked biotin with PEG to synthesize biotin-PEG and then linked PLA with biotin-PEG to synthesize biotin-PEG-PLA polymer through ring-opening polymerization.…”

Section: Synthesis Of Peg-pla End-group Derivativesmentioning

confidence: 99%

Recent advances in PEG–PLA block copolymer nanoparticles

Xiao

Zeng²,

Zhou³

et al. 2010

IJN

121

View full text Add to dashboard Cite

Due to their small particle size and large and modifiable surface, nanoparticles have unique advantages compared with other drug carriers. As a research focus in recent years, polyethylene glycol-polylactic acid (PEG-PLA) block copolymer and its end-group derivative nanoparticles can enhance the drug loading of hydrophobic drugs, reduce the burst effect, avoid being engulfed by phagocytes, increase the circulation time of drugs in blood, and improve bioavailability. Additionally, due to their smaller particle size and modified surface, these nanoparticles can accumulate in inflammation or target locations to enhance drug efficacy and reduce toxicity. Recent advances in PEG-PLA block copolymer nanoparticles, including the synthesis of PEG-PLA and the preparation of PEG-PLA nanoparticles, were introduced in this study, in particular the drug release and modifiable characteristics of PEG-PLA nanoparticles and their application in pharmaceutical preparations.

show abstract

“…Polymeric NPs with targeting ligands are promising candidates for cancer therapy because they can preferentially localize in tumor tissue rather than in non-cancerous tissues in the body (Pardridge, 2007;Pulkkinen et al, 2008). One strategy that has been explored is the application of antibodytargeted NPs (Kocbek et al, 2007;Chen et al, 2008;Sun et al, 2008;Fay et al, 2011;Lei et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Preparation of camptothecin-loaded targeting nanoparticles and their antitumor effects on hepatocellular carcinoma cell line H22

Yang

Yan

et al. 2014

Drug Delivery

View full text Add to dashboard Cite

Camptothecin (CPT) is an effective anticancer agent against various cancers but the clinical application is limited because of its poor water solubility, low bioavailability and severe toxic side effects. The aim of the present study was to evaluate the feasibility of using targeted NPs as a high-performance CPT delivery system that targets liver cancer cells through intravenous (i.v.) administration route. CPT was incorporated into biotin-F127-PLA or F127-PLA polymeric nanoparticles (NPs) by a dialysis method. The preparation of the targeting NPs was performed by conjugating biotin-F127-PLA NPs with anti-3A5 antibody. The antitumor effect of the CPTloaded nanoparticles against H22 cells in vitro was determined using an MTT assay. Tissue distribution and tumor inhibition in vivo were also evaluated. Survivin mRNA expression was assessed by real-time polymerase chain reaction. Results showed that the targeted CPT NPs exhibited regular spherical shapes with a mean diameter of approximately 180 nm. In vitro release of the targeted CPT NPs exhibited an initial burst (40%) within 12 h, followed by a slow release. Cytotoxicity test against H22 cells indicated that the targeted CPT NPs exerted significant antitumor effects. Compared with free CPT and non-targeted CPT NPs, the targeted CPT NPs showed superior inhibition ratio against tumor in vivo, which may be associated with reduced survivin mRNA expression. The results suggested that the new targeted CPT NPs may be a promising injectable delivery system for cancer therapy.

show abstract

Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin–biotin technology: Formulation development and in vitro anticancer activity

Cited by 112 publications

References 38 publications

Thermoreversible Pluronic® F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies

Thermoreversible Pluronic® F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies

Recent advances in PEG–PLA block copolymer nanoparticles

Preparation of camptothecin-loaded targeting nanoparticles and their antitumor effects on hepatocellular carcinoma cell line H22

Contact Info

Product

Resources

About

Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin–biotin technology: Formulation development and in vitro anticancer activity

Cited by 112 publications

References 38 publications

Thermoreversible Pluronic&reg; F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies

Thermoreversible Pluronic&reg; F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies

Recent advances in PEG&ndash;PLA block copolymer nanoparticles

Preparation of camptothecin-loaded targeting nanoparticles and their antitumor effects on hepatocellular carcinoma cell line H22

Contact Info

Product

Resources

About

Thermoreversible Pluronic® F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies

Thermoreversible Pluronic® F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies

Recent advances in PEG–PLA block copolymer nanoparticles